Evaluation of Predictive Proteic Profile on Mortality in the Acute Phase of Septic Shock in Cancer Patients

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

60 participants

Study Classification

INTERVENTIONAL

Study Start Date

2008-08-31

Study Completion Date

2011-05-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The mortality induced by infections in onco-hematological patients is abnormally high at the acute phase of septic shock. Consequently, it is important to detect the population with a high risk of short term mortality among patients with a septic shock. The aim of this study is the evaluation of predictive proteic profile on the short term mortality in the acute phase of septic shock in cancer patients.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Interest of the Balance of Pro-coagulating and Profibrinolytis Activities of the Microparticles (MP) in the Prognosis of Septic Shock

NCT02062970

the Coagulolytic Balance the Mortality Rate the Performance Used to Evaluate the Principal Objective Are Technical Performances, Sensibility and Specificity of the Tests

UNKNOWN NA

Antibiotic De-escalation in Onco-hematology Patients for Sepsis or Septic Shock

NCT03683329

Critical Care Cancer

COMPLETED PHASE3

Prognostic Interest of Leucocyte Immunophenotyping During the Acute Phase of Sepsis

NCT01995448

Sepsis With Acute Organ Dysfunction

COMPLETED

Procalcitonin Monitoring Sepsis Study

NCT01523717

Severe Sepsis Septic Shock

COMPLETED

Comparative Study of the Protein C Pathway in Septic and Non Septic Patients With Organ Failure

NCT00361725

Severe Sepsis Organ Failure

TERMINATED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Method: Monocentric prospective study with diagnostic and prognostic expectations.

Primary objective:

Identification and characterization of early proteic biomarkers predictive of short term mortality in cancer patients with septic shock.

Secondary objective:

Research of clinical and biological prognostic factors.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Sepsis Septic Shock Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

SELDI-TOF MS

The proteic profiling is performed by SELDI-TOF mass spectroscopy.

Group Type EXPERIMENTAL

SELDI-TOF MS for plasmatic proteic profile

Intervention Type OTHER

An extra blood sample is required to determine the plasmatic proteic profile used to identify one or several signatures which are correlated to the clinical evolution (mortality at D30).

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

SELDI-TOF MS for plasmatic proteic profile

An extra blood sample is required to determine the plasmatic proteic profile used to identify one or several signatures which are correlated to the clinical evolution (mortality at D30).

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patient from oncology or hematology with a septic shock
* Patient aged 18 years and older
* Inclusion within the 24 hours of the septic shock in the intensive care unit
* Signed consent according to the emergency reglementation